Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4390901 | 0.99 | MEN1 (0.51) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4377040 | 0.92 | LMNA (0.49) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4383679 | 0.91 | LMNA (0.49) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4385367 | 0.88 | HTT (0.51) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL13588989 | 0.85 | PLA2G1B (0.44) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4379552 | 0.85 | LMNA (0.52) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4383576 | 0.84 | PLA2G1B (0.43) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4382720 | 0.83 | LMNA (0.47) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8219003 | 0.83 | LMNA (0.49) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4391011 | 0.83 | LMNA (0.54) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | MEN1 3694/4885KMT2A 2079/4885LMNA 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.